Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.72 |
| ▸ | TP53 | P04637 | 4/20 | 0.72 |
| ▸ | TSHR | P16473 | 3/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.72 |
| ▸ | KDR | P35968 | 2/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.54 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.54 |
| ▸ | MITF | O75030 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Kinetin SCHEMBL29453466 | 0.85 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53TSHRCYP1A2ADORA3 | |
| Kinetin SCHEMBL15706 | 0.85 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53TSHRCYP1A2ADORA3 | |
| 6-Benzylaminopurine SCHEMBL15067419 | 0.85 | LMNA (0.69) | SMN1; SMN2TP53TSHRCYP1A2ADORA3 | |
| Kinetin SCHEMBL584401 | 0.84 | SMN1; SMN2 (0.97) | SMN1; SMN2TP53TSHRCYP1A2ADORA3 | |
| Kinetin SCHEMBL15941491 | 0.81 | SMN1; SMN2 (0.86) | SMN1; SMN2TP53TSHRCYP1A2ADORA3 | |
| Kinetin SCHEMBL25270416 | 0.80 | SMN1; SMN2 (0.84) | SMN1; SMN2TP53TSHRCYP1A2ADORA3 | |
| Kinetin SCHEMBL30320041 | 0.80 | SMN1; SMN2 (0.84) | SMN1; SMN2TP53TSHRCYP1A2ADORA3 | |
| Ribose (Furanose) SCHEMBL5519867 | 0.78 | CYP1A2 (0.72) | SMN1; SMN2TP53TSHRCYP1A2ADORA3 | |
| Ribose (Furanose) SCHEMBL18789082 | 0.75 | TSHR (0.58) | SMN1; SMN2TP53TSHRCYP1A2ADORA3 | |
| Kinetin SCHEMBL28188657 | 0.75 | SMN1; SMN2 (0.70) | SMN1; SMN2TP53TSHRCYP1A2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229771-B1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIV PALACKEHO (CZ) | 2024-04-03 | — | — | EP | disclosed |
| EP-3229772-B1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIV PALACKEHO (CZ) | 2020-04-29 | — | — | EP | disclosed |
| US-10550144-B2 | 6-aryl-9-glycosylpurines and use thereof | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2020-02-04 | — | — | US | disclosed |
| US-10100077-B2 | 6-aryl-9-glycosylpurines and use thereof | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2018-10-16 | — | — | US | disclosed |
| US-20170334943-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2017-11-23 | — | — | US | disclosed |
| US-20170326168-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2017-11-16 | — | — | US | disclosed |
| EP-3229772-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | Univerzita Palackého v Olomouci (CZ) | 2017-10-18 | — | — | EP | disclosed |
| EP-3229771-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | Univerzita Palackého v Olomouci (CZ) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016091236-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016091235-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2016-06-16 | — | — | WO | disclosed |
| EP-0475160-B2 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| EP-0475160-B1 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 1996-02-14 | — | — | EP | disclosed |
| EP-0475160-A1 | Preparation for drug application in minute droplet form | Cevc, Gregor, Prof. Dr. (DE) | 1992-03-18 | — | — | EP | disclosed |
| WO-1992003122-A1 | PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS | CEVC GREGOR (DE) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326168-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | GART, DAO, GLA | SMN1; SMN2 3612/4885TP53 3135/4885TSHR 2378/4885 |
| US-10550144-B2 | 6-aryl-9-glycosylpurines and use thereof | GART, DAO, GLA | SMN1; SMN2 3612/4885TP53 3135/4885TSHR 2378/4885 |
| US-20170334943-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNG, FUT6, GART | SMN1; SMN2 2553/4885TP53 2090/4885TSHR 2559/4885 |
| US-10100077-B2 | 6-aryl-9-glycosylpurines and use thereof | UNG, FUT6, GART | SMN1; SMN2 2553/4885TP53 2090/4885TSHR 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.